Promising combo tackles aggressive lymphoma in large trial
NCT ID NCT04231448
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 3 trial tested whether adding tucidinostat (an oral HDAC inhibitor) to standard R-CHOP chemotherapy improves outcomes for people with newly diagnosed MYC/BCL2 double-expressor diffuse large B-cell lymphoma, an aggressive subtype. The study enrolled 423 adults who had not received prior treatment. Participants received either tucidinostat plus R-CHOP or a placebo plus R-CHOP for six cycles, with additional tucidinostat for those who achieved complete response. The main goal was to see if the combo extended event-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tucidinostat (chidamide) plus R-CHOP chemotherapy
What this could lead to
If successful, this combination could become a new standard treatment for a hard-to-treat type of lymphoma, improving how long patients stay cancer-free.
What could go wrong
This is a completed Phase 3 trial, but results are not yet widely reported. Adding a drug may increase side effects, and the benefit over standard R-CHOP alone is not yet confirmed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
-
Shanghai JiaoTong University School of Medicine，Ruijin Hospital
Shanghai, Shanghai Municipality, China